New eye drops aim to soothe dry eyes – first human test underway
NCT ID NCT07640867
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether RCI001 eye drops are safe and tolerable in 40 healthy adult men. Participants receive either the active eye drops or a placebo, and researchers monitor for side effects and how the drug behaves in the body. This is a first step toward possibly developing a new treatment for dry eye.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RCI001 eye drops 0.25%
What this could lead to
If safe and well-tolerated, this could lead to further studies testing RCI001 as a treatment for dry eye symptoms.
What could go wrong
This is a very early Phase 1 trial in only 40 healthy men, not people with dry eye. It only tests safety and how the drug moves through the body, not whether it works for dry eye. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul national unversity hospital
Seoul, South Korea